Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Congress Puts Pressure On USTR Over Deal With Canada And Mexico

Executive Summary

More than 100 members of the US Congress have written to US Trade Representative ambassador Robert Lighthizer urging changes to the US-Mexico-Canada Agreement trade deal that is due to replace the previous NAFTA agreement, with biologic competition and access highlighted as key concerns.

You may also be interested in...

AAM Welcomes Potential USMCA Revision

The AAM has welcomed reports that US negotiators for the proposed US-Mexico-Canada trade agreement could be willing to soften demands on intellectual-property protections for pharmaceuticals, including the data exclusivity period for biologics.

AAM Slams USMCA Over Mexico Biologics Impact

Biologic exclusivity provisions in the proposed USMCA US-Mexico-Canada trade agreement will not create a new market for original biologics in Mexico, as firms have been selling them in the country since before 2001, the US Association for Accessible Medicines has argued in response to brand industry claims.

IGBA Aims To Take The Fight To Originators On Trade Deals

 With a permanent structure in place and a trade principles paper recently updated, the IGBA believes it is well placed to argue the case for promoting accessible medicines in international trade negotiations versus the interests of the originator industry.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts